Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

110.49
+1.311.20%
Post-market: 110.24-0.2500-0.23%19:35 EDT
Volume:273.50K
Turnover:30.13M
Market Cap:1.03B
PE:89.53
High:110.70
Open:109.16
Low:108.66
Close:109.18
52wk High:118.00
52wk Low:90.60
Shares:9.34M
Float Shares:9.34M
Volume Ratio:0.90
T/O Rate:2.93%
Dividend:2.14
Dividend Rate:1.94%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):142.30

Loading ...

Abbvie - to Deploy AI Via Valkai Partnership to Improve Clinical Research Efficiency

THOMSON REUTERS
·
Sep 29

Abbvie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

THOMSON REUTERS
·
Sep 29

Allergan Aesthetics Receives Health Canada Authorization for Boey® (Trenibotulinumtoxine), the First and Only Rapid-Onset, Short-Duration Neurotoxin for Frown Lines

THOMSON REUTERS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 29

Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis

TIPRANKS
·
Sep 29

Eli Lilly - Zepbound 10 Mg and 15 Mg Show Comparable Adverse Event Discontinuation Rates to Wegovy Hd

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Shows 4.5% Greater Weight Loss than Wegovy Hd in Adults with Obesity

THOMSON REUTERS
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound Achieves 20.2% Weight Reduction vs 13.7% for Wegovy at 72 Weeks

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Users Have over Three Times the Odds of 20% Weight Reduction vs Wegovy Hd

THOMSON REUTERS
·
Sep 29

Citi Remains a Hold on Merck & Company (MRK)

TIPRANKS
·
Sep 29

Merck Starts Phase 1 Trial of Oral Peptide Developed With Cyprumed's Technology

MT Newswires Live
·
Sep 29

Lilly Touts Foundayo Advantage over Novo's Ozempic Pill in Diabetes Analysis

Reuters
·
Sep 29

Analysts’ Top Healthcare Picks: AbbVie (ABBV), Quantum-Si (QSI)

TIPRANKS
·
Sep 29

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Reuters
·
Sep 29

Novo Nordisk announces retrospective RWE on Ozempic in type 2 diabets

TIPRANKS
·
Sep 29

Eli Lilly announces positive results from study of Foundayo 17.2 mg

TIPRANKS
·
Sep 29

Novo Nordisk Strikes Second Licensing Deal Since Frosty Capital-Markets Day

Dow Jones
·
Sep 29

Scotiabank Adjusts PT on Merck & Co. to $180 From $155, Keeps Sector Outperform Rating

MT Newswires Live
·
Sep 29